Brian Philip

Company: Triumvira Immunologics Inc

Job title: Associate Director of Allogeneic Therapy

Seminars:

Making Solid Tumour Immunotherapy Safer and More Accessible 1:45 pm

TAC T-cell Antigen Coupler technology works directly with the T cell receptor to aid tumour recognition and targeting Closely mirroring the natural T cell response TAC technology offers key advantages including reduced risk of tonic signalling, reduced risk from cytokine release, and retention of memory phenotype on engineered cells TAC design offers potential for both…Read more

day: Day 2 - Track B - Afternoon